NovaQuest Capital Management

Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, focused on developing immunomodulatory treatments for transplantation, rare autoimmune conditions related to immunoglobulin G (IgG), transplant rejection, and cancer. Its lead product candidate, Imlifidase, is an antibody-cleaving enzyme designed to facilitate kidney transplantation in sensitized patients and is being explored for other organ transplants and acute autoimmune diseases. The company is also advancing novel immunoglobulin-cleaving enzymes for repeat dosing in autoimmune diseases, transplantation, and oncology, as well as enzyme-based cancer immunotherapies. Additionally, Hansa Biopharma has a licensing agreement with Axis-Shield Diagnostics Limited for a method that predicts severe sepsis in emergency settings. The company operates primarily in Sweden, other European markets, and the United States, generating most of its revenue from product sales.

Applied Lifesciences & Systems, LLC is a bio-systems company based in Raleigh, North Carolina, established in 2011. The company specializes in developing automated solutions for the detection, targeting, and delivery of vaccines in the poultry, aquaculture, and livestock sectors. Its innovative vaccine delivery system aims to enhance current vaccination methods by ensuring that each chick receives an accurate and consistent vaccination. This precision not only boosts the natural immune response to diseases but also improves overall flock health, contributing to cleaner and healthier poultry. Applied Lifesciences & Systems is committed to advancing animal health and productivity through its cutting-edge technology.

Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company specializing in medical dermatology therapeutics. The company's lead product candidate, Tapinarof, is a topical cream undergoing Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Dermavant's pipeline includes additional candidates in various stages of development, such as Cerdulatinib, which targets vitiligo and other inflammatory skin conditions, and Oxybutynin/Pilocarpine, an oral therapy for primary focal hyperhidrosis. Preclinical candidates include DMVT-503, aimed at treating acne vulgaris, and DMVT-501, a potential treatment for atopic dermatitis. Dermavant Sciences has established licensing agreements with several pharmaceutical companies and operates as a subsidiary of Roivant Sciences Ltd. The company, originally known as Roivant Dermatology Ltd., rebranded in June 2016 and is based in London, United Kingdom.

Argenta is a contract research organization and contract manufacturing organization that specializes in animal health. The company offers a range of services, including pre-clinical development and the manufacturing of veterinary products such as solid dose tablets, topical liquids, sterile injectables, and oral liquids. With facilities located in New Zealand, the United Kingdom, and the United States, Argenta provides comprehensive product development services to clients globally, catering to various scales of production needs.

Aceragen is a developer of therapeutic treatments intended for rare and ultra-rare diseases.

Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training, and compliance monitoring tools, and real-time data & predictive analytics.

CoreRx™ is a contract pharmaceutical development organization that helps get products into the clinic faster, providing a complete spectrum of cGMP solutions for pharmaceutical dosage form development. Our wide range of support services, extensive instrumentation and rigorous quality systems provide timely results communicated in a clear, efficient and consistent manner.

Mileutis LTD is a biopharmaceutical company based in Ness Ziona, Israel, founded in 2004. It focuses on the discovery, development, and commercialization of biologically sourced therapies for both animal and human health. The company's primary offerings include Imilac, an intramammary solution designed for use at the beginning of the dry period, which aids in the management and prevention of bovine mastitis, and Milac, intended for treating intramammary infections during lactation. Mileutis is committed to developing natural and novel peptides that address chronic and infectious diseases, aiming to reduce antibiotic use in both human and animal health sectors while enhancing productivity in veterinary dairy management.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

InformedDNA is a provider of genetics benefits management services that connects genetic counselors to patients, enhancing access to genomic expertise in healthcare. As the nation's largest independent network of genetics specialists, the company offers a comprehensive evidence-based knowledge library focused on genetic tests and hereditary conditions. InformedDNA supports health plans, health systems, and providers by offering services such as policy development, prior authorization for genetic testing and specialty drugs, and utilization analytics. Their approach emphasizes personalized care and informed decision-making, with the goal of optimizing healthcare spending while improving patient outcomes. By facilitating direct access to genetics experts, InformedDNA empowers healthcare providers to utilize cutting-edge genetic insights effectively, ensuring patients receive appropriate testing and care.

Nevakar Inc. is a pharmaceutical company based in Bridgewater, New Jersey, established in 2015. The company specializes in developing innovative ophthalmic and injectable products, aiming to enhance existing FDA-approved molecules to meet unmet clinical and commercial needs. Nevakar's operations are supported by a state-of-the-art research and development infrastructure located in the New Jersey Center of Excellence, coupled with a knowledgeable management and leadership team that guides its intensive research and clinical efforts.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Roivant Sciences is a commercial-stage biopharmaceutical company focused on enhancing healthcare delivery through innovative drug development. The company aims to reduce the time and cost associated with bringing new medicines to market, sharing those savings with the healthcare system. Roivant achieves this by creating specialized entities known as Vants, which are agile biotech and healthcare technology firms that leverage unique talent sourcing and technology deployment strategies. In addition to its biopharmaceutical subsidiaries, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its drug candidates, VTAMA (tapinarof) is designed for the treatment of plaque psoriasis and has reached the commercial stage, while several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, are in various stages of development.

Mesoblast Limited is a biopharmaceutical company focused on developing and commercializing allogeneic cellular medicines for various complex diseases. Headquartered in Melbourne, Australia, the company utilizes its proprietary Mesenchymal Precursor Cell (MPC) technology to address conditions such as cardiovascular disorders, orthopedic spine issues, oncology, hematology, and immune-mediated diseases. Key products in clinical development include MSC-100-IV for steroid refractory acute graft versus host disease, MPC-150-IM for advanced heart failure, and MPC-06-ID for chronic low back pain. Additionally, Mesoblast is advancing MPC-300-IV in Phase II trials for biologic refractory rheumatoid arthritis and diabetic kidney diseases. The company collaborates with partners like Tasly Pharmaceutical Group and JCR Pharmaceuticals to expand its offerings in global markets, including the United States, Australia, Singapore, the United Kingdom, and Switzerland. Founded in 2004, Mesoblast aims to provide innovative therapies where conventional treatments have limited efficacy.

Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions tailored for the clinical research sector, assisting sites, sponsors, and contract research organizations (CROs) in streamlining their processes. The company's primary offering, SureSource, is an electronic source platform designed to capture essential clinical trial data and documents directly at the research site. Additionally, Clinical Ink provides Lunexis ePRO+, which facilitates patient participation by allowing flexible engagement options, and CentrosHealth, a platform that keeps patients informed and compliant throughout their clinical trial experience. Founded in 2006, Clinical Ink operates its headquarters in Horsham, Pennsylvania, and has additional offices in Winston-Salem, Cary, Philadelphia, and Cambridge. The company aims to enhance clinical trial workflows and improve data quality through its innovative electronic source solutions.

Azurity Pharmaceuticals is a developer of drug products and technologies to address the needs of patients. Its drug products such as antimicrobial, mouthwashes, and testosterone enable pharmacists to prepare drugs for those populations who are in need of a better alternative to traditionally-compounded medications.

Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.

Myovant Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for women's health and endocrine diseases. The company's primary product is relugolix, an oral, once-daily medication that functions as a gonadotropin-releasing hormone receptor antagonist, targeting conditions such as heavy menstrual bleeding associated with uterine fibroids, endometriosis-related pain, and advanced prostate cancer. Additionally, Myovant is advancing MVT-602, an oligopeptide kisspeptin agonist aimed at treating female infertility in assisted reproduction. The company collaborates with Pfizer to enhance the development and commercialization of relugolix in both oncology and women's health. Founded in 2016 and based in London, Myovant Sciences was previously known as Roivant Endocrinology Ltd. and currently operates as a subsidiary of Sumitovant Biopharma Ltd.

PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

BioCritica is a biotechnology company dedicated to addressing the critical care needs of patients and healthcare professionals within the hospital sector. The company is known for its sepsis treatment, Xigris, and is actively working on a pipeline of additional products aimed at enhancing patient care. BioCritica's mission centers on developing and commercializing innovative solutions that significantly improve the quality of life for individuals facing severe medical conditions.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.

Protemix is a biopharmaceutical company that discovers, develops, and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes, and other metabolic disorders. The company was founded in 1999 and is based in Auckland, New Zealand with an additional office in San Diego, California.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Sirion Therapeutics is a Tampa, FL-based company dedicated to the development and commercialization of innovative ophthalmic products.